

Allianz Life World Healthscience Fund

May 2026

Investment Objective

The Allianz Life World Healthscience Fund (the "Fund") seeks to maximise total return by investing globally in the equity securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology.


Terms	YTD	1 month	3 months	6 months	1 year	Since Inception (Annualised)
Allianz Life World Healthscience Fund	-5.27%	4.27%	-3.30%	-7.66%	3.17%	-5.47%
Benchmark: MSCI World Healthcare Index*	-3.01%	1.92%	-6.75%	-3.78%	12.09%	3.08%
Target Fund (USD)	-4.01%	4.54%	-5.59%	-4.82%	10.71%	1.81%

RM appreciated 2.07% (YTD) and appreciated 8.04% (since inception (annualised))

*Source: Bloomberg and <https://www.blackrock.com/uk>

The above performance is calculated in Ringgit Malaysia on a NAV-to-NAV basis. It is strictly the performance of the investment fund and not the returns earned on the actual premiums paid of the investment-linked product. Past performance is not an indication of future performance.

Performance Since Inception



Portfolio Composition by Asset Type

Target Fund	97.1%
Cash & Deposit	2.9%

Facts on Target Fund	Key Fund Facts (at 31 May 2026)
Name	BGF World Healthscience Fund
ISIN	LU0122379950
Type	Undertaking for Collective Investment in Transferable Securities
Fund Manager	BlackRock (Luxembourg) S.A.
Fund Currency	USD
	Fund Size
	RM45.776 million
	Risk Profile
	Moderate to high
	Launch Date
	21 February 2024
	Fund Currency
	Ringgit Malaysia
	Investment Manager
	Allianz Life Insurance Malaysia Berhad
	Pricing Frequency
	Daily
	Price per Unit - Bid ¹
	RM0.880
	Management Fee
	1.50% p.a
	Other Charges ²
	Include but not limited to government tax, auditor fee, custodian fee & transaction charges

Portfolio Analysis of Target Fund

Source: <https://www.blackrock.com/uk>

Geographic Breakdown (%)

UNITED STATES	73.32
SWITZERLAND	11.59
UNITED KINGDOM	6.89
BELGIUM	1.48
DENMARK	1.46
ISRAEL	1.37
CHINA	0.85
GERMANY	0.83
JAPAN	0.81
FRANCE	0.75
OTHER	0.66

Sector Breakdown (%)

PHARMACEUTICALS	48.79
BIOTECHNOLOGY	21.35
HEALTH CARE PROVIDERS & SERVICES	11.00
HEALTH CARE EQUIP. & SUPPLY	9.86
LIFE SCIENCES TOOLS & SERVICES	8.33
CASH AND/OR DERIVATIVES	0.66

Top 10 Holdings (%)

ELI LILLY	10.21%
JOHNSON & JOHNSON	8.87%
ASTRAZENECA PLC	5.49%
UNITEDHEALTH GROUP INC	5.31%
ROCHE PS PAR AG	4.70%
NOVARTIS AG	4.47%
MERCK & CO INC	4.23%
ABBVIE INC	4.19%
GILEAD SCIENCES INC	3.70%
AMGEN INC	2.75%
Total of Portfolio	53.92%

Allianz Life World Healthscience Fund

May 2026

1. The price per unit of the Fund is the total market value of assets in the Fund divided by the total number of units of the Fund. To ensure fair treatment to all unit holders, transaction costs of acquiring and disposing of assets of the Fund are recouped by making a dilution or transaction cost adjustment to the NAV per unit of the Fund. Allianz Life Insurance Malaysia Berhad retains the right to suspend issuance or redemption of units of the Fund under exceptional circumstances, e.g. temporary closure of any stock exchange, as disclosed in the fund brochure.
2. Expenses directly related to and necessary in operating the Fund.

Disclaimer:

The Fund is a unit-linked fund offered by Allianz Life Insurance Malaysia Berhad ("Allianz"). This fact sheet is prepared by Allianz and is for information only. The fund fact sheet of the Target Fund will be available at <<https://www.blackrock.com/uk>>. The performance of the Fund is not guaranteed and the value of the units and the income derived there from may increase or decrease. Past returns and any forecast is not necessarily a guide to future performance. Allianz does not warrant or make any representations that the Fund will guarantee profits, or not result in losses or the correctness, accuracy, reliability, or otherwise of this fact sheet. Before deciding to invest in the Fund, you should carefully consider your investment objectives, level of experience, and risk appetite. Allianz disclaims any and all liabilities against loss, damages, etc whether direct, indirect or consequential as a result of your reliance on this fact sheet. You should be aware of all the risks associated with fluctuations in a unit-linked fund and are advised to seek the advice of your financial consultant before making any investment.

For MSCI's disclaimer, please refer to <https://www.msci.com/notice-and-disclaimer-for-reporting-licenses>.